Aortopathy associated with congenital heart disease : a current literature review by Francois, Katrien
Vol 8/ Issue 1/ January-April 2015
Official Publication of Pediatric Cardiac Society of India
Editorial
Partnership in healthcare: What can the west learn from the delivery
of pediatric cardiac care in low- and middle-income countries 
Seshadri Balaji, Raman Krishna Kumar 
Original Articles
Tetralogy of Fallot with subarterial ventricular septal defect:
Surgical outcome in the current era 
Vimalarani Devendran, Prakash R Anjith, Anil Kumar Singhi, Vimala Jesudian,
Ejaz Ahmed Sheriff, Kothandam Sivakumar, Roy Varghese    
e-Teaching in pediatric cardiology: A paradigm shift 
Sunita Maheshwari, Bistra Zheleva, Veeralakshmi Rajasekhar, Bipin Batra
Association of temporary complete AV block and junctional ectopic
tachycardia after surgery for congenital heart disease 
Christian Paech, Ingo Dähnert, Martin Kostelka, Meinhardt Mende, Roman Gebauer
Pediatric echocardiograms performed at primary centers:
Diagnostic errors and missing links! 






















































25Annals of Pediatric Cardiology 2015 Vol 8 Issue 1
Address for correspondence: Dr. Katrien Francois, Department of Cardiac Surgery, University Hospital Gent, De Pintelaan 185, 9000 Gent, Belgium. 
E-mail: katrien.francois@ugent.be
INTRODUCTION
Dilatation of the aortic root and the ascending aorta 
is frequently encountered in patients with congenital 
heart disease (CHD) at initial presentation and during 
follow-up.
Primary aortic dilatation is mainly associated with 
coarctation of the aorta (CoA), bicuspid aortic valve 
(BAV), and conotruncal abnormalities such as tetralogy 
of Fallot (TOF), pulmonary atresia with ventricular septal 
defect (PA/VSD), or truncus arteriosus. It can be a key 
feature in genetic syndromes with connective tissue 
disorders, such as Marfan, Loeys-Dietz, vascular Ehlers-
Danlos, aneurysm-osteoarthritis, and Turner syndrome. 
Secondary dilatation of the aortic root and to a lesser 
extent of the ascending aorta is seen after congenital 
cardiac surgery, when the original aortic root is replaced 
by a pulmonary autograft, as in the Ross operation, or 
modified as in the arterial switch operation (ASO) or 
systemic outflow tract reconstruction in single ventricle 
(SV) patients. In these situations the neo-aortic root 
consists mainly of pulmonary arterial root tissue 
introduced in the high-pressure left-sided system, often 
leading to dilatation in a time-dependent fashion.
The dilatation of the aorta or the neo-aortic root cannot 
be considered as a stand-alone characteristic, but 
needs to be regarded as part of the aorto-ventricular 
complex, comprising the systemic ventricle, the aortic 
valve, the aortic root, and the aortic vascular wall. Each 
component of this complex may by itself influence the 
other components, thus introducing a dysfunction at 
multiple levels, often defined as “aortopathy”.[1]
The magnitude of this problem continues to grow; as 
large cohorts of surgically treated patients survive 
into adulthood. Over the last decade, cumulative 
documentation of progressive aortic pathology in 
patients with CHD has been published. 
The objective of this review is to summarize the current 
knowledge on aortic pathophysiology, diagnostic tools, 
and options and guidelines for prevention and treatment 
of the dilated aortic root and ascending aorta, associated 
with CHD. The aortic dilatation in genetic syndromes 
will not be discussed, as it presents a very large topic 
with specific features, not always applicable to patients 
with CHD.
MORPHOGENESIS OF THE AORTIC AND 
PULMONARY ROOT
The aortic and pulmonary trunks originate from the 
remodeling of the pharyngeal arch arteries during 
the early embryonic development. The original six 
symmetrical arteries, attached to the dorsal aorta, 
give rise to the ascending aorta (partly derived from 
the left fourth artery), and pulmonary trunk (derived 
from the left sixth artery), with two branch pulmonary 
arteries attached.[2] Neural crest cells migrate to the 
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caudal pharyngeal arches and into the common outflow 
truncus of the primitive heart tube, participating in 
distal septation of the common outflow tract into two 
independent separate extra-pericardial vessels. The 
formation of the semilunar valves of the aorta and 
pulmonary trunk evolves from the differentiation of 
the mesenchymal wedges of the proximal truncus into 
valvular tissue, thus contributing to the intra-pericardial 
portions.[3] [Figure 1]
A lot of controversy exists about the origin of the 
smooth muscle cells in the tunica media of the arterial 
trunks. From the onset of its development, the truncus 
wall is encircled by myocardial cells from the second 
heart field.[4] Some suggest that these cells may change 
from a myocardial phenotype to an arterial one;[5] 
others considered that the initial population of cells 
surrounding the outflow tract originate from neural crest 
cells,[6] that differentiate into tunica media and tunica 
adventitia, with the exception of the intra-pericardial wall 
of the aortic and pulmonary trunk, whose components 
are myocardial cells and vascular smooth muscle cells 
(VSMC) derived from the second heart field.[7]
In utero, the developing pulmonary artery is exposed 
to pressures identical to these of the fetal systemic 
circulation in the absence of flow through the lungs, as 
both outflow tracts are connected through the ductus 
arteriosus.[8] Studies in sheep have demonstrated that 
each of the major components of the arterial walls 
(elastin, collagen, and VSMC) undergo important changes 
in the perinatal period, induced by changes in local 
hemodynamic conditions, thus influencing the structural 
composition of the main arteries.[9,10]
At birth, systemic arterial pressure and aortic flow 
increase as a result of the decrease in pulmonary vascular 
resistance, the closure of shunts, and the disappearance 
of the placental vascular bed. In the week surrounding 
birth, very rapid accumulation of elastin and collagen 
in the aorta has been noted, more pronounced in the 
thoracic than in the abdominal aorta.[10] At the same 
time the pressure in the pulmonary artery drops, and 
after closure of the ductus arteriosus, it receives all of 
the right ventricular output in a high flow/low pressure 
circulation. As a result, the wall thickness, the elastin 
and collagen content become significantly higher in the 
proximal ascending aorta than in the pulmonary artery 
a few weeks after birth, while the percentage of VSMCs 
in both trunks is comparable.[8]
There is evidence that new changes in differential flow 
or pressure through both great vessels after neonatal life 
may induce continuous changes in the smooth muscle 
and collagen content through regulatory signals from 
the vascular extracellular matrix.[11] The elastin content 
in the vascular wall, however, does not change much after 
birth because of its very low turnover and long half-life 
of about 40 years. Following post-natal development, 
expression of elastin drops to low levels, and remains 
low throughout life.[12]
All these mechanisms may help to understand some of 
the findings noted in the dilated aorta of children with 
CHD.
PRIMARY AORTIC DILATATION 
ASSOCIATED WITH CHD
The prevalence of a primary dilated aorta is high 
in association with CoA, BAV, and conotruncal 
abnormalities. Often the large aorta is already noted 
at the fetal echocardiography, and may be used as a 
distinct diagnostic feature. The evolution of the aortic 
size after birth will result from a combination of intrinsic 
pathology, associated malformations, surgical or catheter 
interventions, and control of risk factors later in life; 
they may all influence the natural course of the aortic 
dilatation.
Coarctation of the aorta
CoA accounts for 5-8% of CHD.[13] Isolated forms occur 
in less than half of the patients, CoA is often found in 
combination with BAV and mitral valve anomalies. It is 
usually sporadic, but genetic influences can play a role: 
There is a male predominance of 1,5-1,7/1, and 10-15% 
of Turner syndrome patients have aortic CoA.[14]
Patients that are symptomatic in the neonatal period 
often present with a variable degree of aortic arch 
hypoplasia, and when a VSD is associated, the ascending 
aorta is usually not enlarged due to the preferential 
flow through the pulmonary artery. A dilated ascending 
aorta and aortic arch can be found in patients with a 
previously undetected significant CoA, that present in 
Figure 1: Schematic representation of migration of the neural crest 
cells to the caudal pharyngeal arches and the common outflow 
tract prior to remodeling of the aortic arch arteries. Adapted from 
Snider et al. (ref. 2)
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adolescence or adulthood with upper limb hypertension, 
an incidental murmur, or exertional leg fatigue.[14] In a 
long-term follow-up study of patients after CoA surgery, 
Stewart et al., found a dilated aortic root and arch in 
16%. There was a trend to a more abnormally widened 
aorta in patients that had surgery later in life, and 
5 of the 6 patients out of their series that died from 
aortic aneurysm rupture, had original surgery at a 
mean age of 19 years, and were known with associated 
hypertension.[15]
It is unsure if early repair of CoA will always be able 
to prevent late aortic dilatation. We know that even 
neonatal intervention does not prevent the occurrence 
of late hypertension, which by itself may trigger 
aortic dilatation.[16] Biopsy studies comparing the 
aortic wall structure above and below the CoA, have 
shown increased amounts of collagen and a decreased 
smooth muscle cell content in the pre-stenotic region, 
with near normal findings distally, even in young 
children.[17] A functional study in patients with repaired 
CoA demonstrated an impaired flow-mediated dilatation 
and increased vascular stiffness in the brachial artery. 
However, in this study, CoA repair before 4 months of 
age was associated with preserved elastic properties 
of the upper limb arteries, but reduced reactivity 
remained.[18]
Bicuspid aortic valve
The BAV is the most frequent congenital cardiac 
malformation, with a prevalence of 1-2% in the general 
population. Concomitant aortic dilatation is seen in 
80% of patients.[19] Three valve morphologies have been 
identified: Type I (the most prevalent, 69-85%) has a 
fusion of right and left coronary cusps, type II is fusion 
of right and non-coronary cusps, and type III (the least 
prevalent) shows fusion of the left and non-coronary 
cusp. The concomitant aortic dilatation can be confined 
to the ascending aorta, the aortic root, or extend from 
the aortic annulus up to the proximal aortic arch. The 
descending aorta is usually not dilated.[20] The lifetime 
risk of aortic dissection in patients with BAV has been 
reported to be 9 times higher than that of the general 
population.[21]
It has long been thought that the dilated aorta was a 
sole consequence of the altered blood flow through the 
eccentrically opening bicuspid valve and the resulting 
asymmetrical wall stress (the hemodynamic theory), but 
our understanding of this disease entity has evolved ever 
since. Many studies have pointed out that the dilatation 
results from a combination of intrinsic aortic wall 
modifications (the genetic theory) and hemodynamic 
changes induced by the bicuspid valve.[22,23] The 
marked heterogeneity of BAV disease leads to different 
phenotypes, resulting in a large clinical variation of BAV 
patients.
The BAV inheritance pattern is autosomal dominant 
with incomplete penetrance of 9 to 30%.[24] The male 
predominance of 3/1 and the association with Turner 
syndrome suggest an X-linked etiology. Mutations in the 
ACTA2 and NOTCH1 genes have been found in some BAV 
patients, but not the FBN1 gene associated with Marfan 
syndrome. 
The strong association of BAV with CoA may indicate 
that BAV disease involves the ascending aorta and aortic 
arch extending to the ligamentum arteriosum [Figure 2]. 
The fact that the pulmonary trunk in BAV patients shows 
histological changes similar to those seen in the ascending 
aorta, points to a development spectrum involving that part 
of the great vessels that is derived from neural crest cells.[25]
Recent evidence has indicated that dilatation of the 
ascending aorta occurs as a consequence of aortic medial 
degeneration, similar to the one seen in connective 
tissue disorders resulting from apoptosis of neural crest 
derivatives.[21,26] Immunohistochemistry studies in the 
ascending aorta of BAV patients show non-inflammatory 
loss of VSMCs with multifocal apoptosis, in contrast with 
the significant inflammation and cystic medial necrosis 
that is usually found in the dilated aortas of patients 
with tricuspid aortic (TAV) valves.[27] BAV patients have 
been found to show a genetic profile characterized 
by over-expression of polymorphisms of matrix 
metalloproteinase-9 (MMP-9) and MMP-2, and reduced 
expression of MMP-14, compared to patients with TAV 
and dilated aorta.[27-29] The extracellular matrix plays an 
important role in maintaining the structural integrity 
of the vascular wall, and is under the balanced control 
of MMPs and its specific tissue inhibitors. A disturbed 
balance with increased MMP activity, as found in BAV 
aortas, can lead to apoptosis and degeneration of the 
aortic wall, and predispose to aneurysm formation. 
Figure 2: Schematic diagram of the anatomic boundaries of BAV 
disease. The structures involved in BAV disease (in pink) include 
the aortic valve, aortic annulus, sinuses of Valsalva, sinotubular 
junction, ascending aorta, pulmonary trunk and coronary ostia. 
Adapted from Tadros et al. (ref. 21)
Francois: Aortopathy associated with congenital heart disease
28 Annals of Pediatric Cardiology 2015 Vol 8 Issue 1
Dilatation in BAV patients occurs earlier in life than in 
TAV, where aortic distension seems more related to age 
and hypertension.[27] In asymptomatic BAV patients with 
normally functioning valves, the mean aortic diameter 
is usually larger than in their TAV peers of the same 
age.[22,25] Long-term follow-up studies have shown that 
ascending BAV aortas continue to expand at a higher rate 
than TAV aortas, ultimately leading to a higher rate of 
late aortic events and reoperation, despite aortic valve 
replacement.[30,31]
Notwithstanding this growing evidence for the genetic 
theory, it must be acknowledged that hemodynamics 
play an important role in the development of aortic 
dilatation. The histological and biomolecular changes 
described above often show an asymmetric spatial 
distribution, pointing towards a flow-related change.[32]
Four-dimensional flow MRI studies have demonstrated 
turbulent flow and changes in regional wall shear stress 
distribution related to the orientation of the BAV: Type 
I cusp orientation induces increased shear stress on the 
right-anterior wall, type II on the right-posterior wall 
of the aorta. Dilatation of the aortic root or involving 
the entire ascending aorta and arch was found in the 
majority of patients with type II orientation, but not in 
type I.[33,34] However, Jackson et al., could not identify a 
pattern of aortic dilatation in relation to valve orientation 
in a large number of surgical BAV patients.[35] Della Corte 
et al., rather found a relationship between the aortic 
valve pathology and the location of the aortic dilatation: 
Mid-aortic dilatation was more associated with aortic 
valve stenosis, suggesting a post-stenotic dilatation, 
where root dilatation was more prevalent in young men 
and aortic incompetence, and unrelated to the presence 
or severity of stenosis.[22]
The discovery of true detrimental flow patterns and 
pathological genes in association with aortic dilatation 
in BAV patients may help to identify high-risk geno-
phenotypes, improving risk stratification and treatment 
choice.
Conotruncal anomalies: Tetralogy of Fallot and 
pulmonary atresia/ventricular septal defect
TOF is the most common form of cyanotic CHD and 
accounts for 10% of all congenital heart defects. Dilatation 
of the proximal aorta is a common feature in patients 
with unrepaired TOF and PA/VSD, which can already be 
observed at fetal echocardiography. The aorta in TOF is 
dilated mainly at the root, tapering down towards the 
ascending aorta; the aortic arch is usually of normal size. 
Corrective surgery has dramatically improved long-
term prognosis, with nearly 90% of patients now 
surviving well into adulthood.[36] However, persistent 
aortic root dilatation is increasingly reported in adult 
patients, years after corrective surgery. Single case 
reports of progressive aortic dilatation long after 
repair of TOF began appearing in the early 1970s. In 
1982 Capelli and Somerville mentioned persistence 
of a large aortic root, but considered it an acquired 
feature due to long-standing volume overload by years 
of aortopulmonary shunts before complete repair, and 
suggested that earlier repair in the first decade of life 
might prevent this complication.[37] In 1997 the first 
series on progressive aortic root dilatation many years 
after TOF repair was published by the Mayo Clinic 
group.[38] Despite excellent clinical results, a substantial 
cohort of patients developed progressive aortic dilatation 
and subsequent aortic valve incompetence, necessitating 
reoperation on the aortic root. 
The underlying mechanism of the aortic dilatation 
in conotruncal abnormalities is unclear; both 
hemodynamic[37] and intrinsic wall abnormalities[38-40] 
have been suggested. It has been attributed to left-
sided volume overload in the context of right outflow 
obstruction and right-to-left shunt, and seems to be 
more pronounced in the pulmonary atresia variant. 
A right-sided aortic arch, male gender, history of an 
aortopulmonary shunt, and complete repair at older 
age have been associated with late aortic dilatation.[41] 
Some have suggested a genetic factor to be implicated, 
as 22q11 deletion and FBN1 mutations have been 
associated with TOF.[42,43] Intrinsic aortic pathology can 
be coexistent, as histological studies in children of all 
ages with TOF have shown fibrosis, fragmentation of 
elastin, and cystic medionecrosis both on biopsies and 
post-mortem specimen, wall changes similar to those 
seen in Marfan patients with aortic dilatation, however 
often in patients operated late.[39,40] The age at repair may 
play a role in the severity of the histological disturbance: 
In a homogeneous patient cohort that we repaired 
at the age of 6 months, we found less pronounced 
histological changes in the aortic wall, mainly fibrosis and 
accumulation of ground substance. No VSMC necrosis 
or apoptosis was demonstrated, and in only 1 patient 
with a very large aorta some degree of elastin fiber 
fragmentation was found.[44] We speculate that increased 
fibrosis may be the first feature of aortic degradation, and 
that, once medionecrosis, smooth muscle cell disarray, 
and severe elastin fragmentation have occurred, repair 
mechanisms may not be able to completely restore the 
aortic wall integrity after TOF repair. This may explain 
why increased stiffness and higher pulse wave velocity in 
the aorta of repaired TOF patients have been described, 
several years after correction.[45-47]
We and others have demonstrated a significant regression 
of indexed aortic root diameters over time after early 
repair in infancy, with a chance of normalizing the 
initially dilated root within 7 to 8 years.[48,49] In a 
homogenous cohort of TOF patients repaired early in 
infancy, we found that the ascending aortic size really 
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decreases with growth of the patient during the first 
years after surgery, irrespective of the total histology 
score at operation[44] [Figure 3]. These findings support 
the presumption that mitigation of the transaortic flow 
by early surgical repair of TOF triggers a remodeling 
process that may interrupt the progression of the 
limited histological alterations of the aortic root related 
to increased aortic stiffness, thus preventing late aortic 
dilatation.
The real prevalence and severity of dilated aortic 
root and its associated complications in the adult TOF 
population remain to be defined, as more evidence 
emerges that not all patients develop important aortic 
dilatation. In a recent review Mongeon et al. found, in 
adult patients, 35 years after repair of TOF at a mean of 
7 years of age, an aortic dimension of ≥40 mm in 29%, but 
only an observed-to-expected aortic root dimension ratio 
of >1.5 in 7%, and moderate to severe aortic regurgitation 
in 3.5% of patients.[50] Only 3 cases of aortic dissection 
late after TOF repair have been described in the literature 
so far, all in severely dilated aortas of >70 mm.[51-53] In 
the section on guidelines for treatment, these findings 
will be taken into account. 
Secondary aortic dilatation after repair of CHD
In this section we will consider the occurrence of 
dilatation of the aortic root, and to a lesser extent of 
the ascending aorta, after congenital cardiac surgery, by 
which the original aortic root is replaced by a pulmonary 
autograft, as in the Ross operation, or modified as in 
the ASO or systemic outflow tract reconstruction in SV 
patients. In these situations the neo-aortic root consists 
mainly of pulmonary arterial root tissue introduced in 
the high-pressure left-sided system, often leading to 
dilatation in a time-dependent fashion. In contrast with 
the primary aortic dilatation, the literature on secondary 
aortic dilatation is less extensive, probably because this 
feature only started to emerge as a clinical problem 
during the last decade. 
After Ross procedure
Since the introduction by Sir Donald Ross in 1967 of 
the Ross procedure, comprising aortic replacement by 
the pulmonary autograft, this operation has gained 
widespread applicability both in children and adults 
with congenital aortic valve disease.[54] Technically, the 
pulmonary autograft can be implanted as a full root 
replacement, or as a subcoronary replacement, inserting 
the pulmonary autograft as an inclusion cylinder in the 
existing aortic root. The right ventricular outflow tract 
reconstruction is mostly performed with a pulmonary 
homograft or biological xenograft root. 
In growing children, where only the full root replacement 
can be used, the procedure has remained the first choice 
for aortic replacement, because of its potential for growth 
of the neo-aortic root along with the patient’s somatic 
growth, thus preventing the need for repetitive aortic 
reoperations. In adults, after a first wave of enthusiasm, 
the popularity of the technique has dropped during the 
last decade, after several reports of disproportionate neo-
aortic root dilatation and secondary aortic incompetence 
occurring a few years after the original operation. In 
the German-Dutch Ross Registry, the rate of autograft 
re-interventions was significantly higher in adults than 
in children.[55] Freedom from autograft reoperation has 
been reported between 74% and 93% at 10 years,[56-59] 
and between 65% to 82% at 15 years.[60,61] The freedom 
from more than moderate autograft regurgitation is 
reported between 56% and 85% at 10 years, but aortic 
incompetence by itself does not always necessarily 
trigger reoperation.[58,59] A relationship exists between 
increasing valve regurgitation and progressive dilatation 
of sinotubular junction and ascending aorta.[62]
The neo-aortic root after the Ross procedure dilates 
mainly at the sinus portion and the sinotubular junction, 
and less at the neo-aortic annulus itself, that usually 
grows in proportion to the somatic growth in children.[62] 
Dilatation occurs rapidly within the first days after 
surgery, with a further increase during the first year of 
follow-up, without causing significant aortic regurgitation 
in the medium-term phase.[63] In a study in children, 
Solymar et al., demonstrated that during the first year 
after the operation, the mean z-value of the proximal 
autograft increased from 0.2 to 2.2, indicating a more 
rapid increase than predicted, and significantly higher 
than in controls, suggestive of passive dilatation in the 
early postoperative period.[64] After the first year, z-value 
changes in patients and control subjects were very 
similar. The postoperative distension of the pulmonary 
autograft leads to remodeling of the wall and the valve 
Figure 3: Evolution of indexed aortic root diameters after correction 
for tetralogy of Fallot. AnI: Indexed aortic annulus diameter; 
SinI: Indexed sinus diameter; STJI: Indexed sinotubular junction 
diameter. *P < 0.05 for change at each aortic root component; § 
P < 0.05 for change at level of anulus and sinus. Adapted from 
François et al. (ref. 44)
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leaflets, as was demonstrated by the finding of intimal 
thickening, medial elastin fragmentation, hypertrophic 
smooth muscle cells, increased medial and adventitial 
fibrosis, and thickening of valve leaflets in pulmonary 
autografts explanted for various reasons.[65] As the Ross 
operation is applied for BAV disease in 65% to 81% of 
cases,[55,66] the intrinsic pulmonary wall abnormalities as 
described in BAV may enhance the neo-aortic dilatation 
on top of the distension due to the introduction of the 
pulmonary valve in the systemic circulation.[21]
Risk factors for neo-aortic root dilatation have been 
searched for, in order to improve the long-term results 
and diminish the risk for late neo-aortic valve failure. 
Patient factors related to neo-aortic root dilatation and 
a shorter time to autograft reoperation are the presence 
of preoperative pure aortic incompetence,[55-57,61] and 
older age.[62]
Technical factors implicated in increasing neo-aortic 
root diameters are somehow controversial, but mostly 
relate to freestanding root replacement as compared 
to subcoronary implantation,[55,66] and the absence 
of annulus reinforcement strips in an aortic root of 
>28 mm,[57] a surgical modification that may prevent late 
annular dilatation.[55] In adults, equivalent and durable 
results were obtained with subcoronary implantation 
compared to root reinforcement with a tissue or synthetic 
strip.[57] In the more recent years the application of a 
Dacron tube for external support of the pulmonary 
autograft, to prevent sinus and sinotubular junction 
dilatation in freestanding roots, has gained renewed 
interest.[67] A combined ascending aortic replacement for 
aneurysm had no influence on late autograft function in 
a 5-year follow-up study, but the long-term fate of the 
neo-aortic valve in this setting is not known.[59]
After arterial switch operation
Over the past two decades, the ASO has become the 
procedure of choice for repair of transposition of the 
great arteries in neonates and young infants.[68,69] The ASO 
leads to anatomic correction, in contrast to atrial switch 
operation, and thus avoids the long-term complications 
of systemic atrioventricular valve regurgitation and 
ventricular failure. However, several factors are of 
potential concern for the evolution of the neo-aortic root 
later in life. After ASO, the native pulmonary valve and 
root assume the role of systemic arterial valve and root. 
As was described previously, the pulmonary and aortic 
valves are macroscopically indistinguishable at birth, but 
the aortic valve develops more collagen and elastin fibers 
in the perinatal period.[10] It has been demonstrated, 
however, that the structural changes in the medial 
connective tissue of the pulmonary trunk, that normally 
accompany decreasing pulmonary arterial pressure in 
infants, do not occur if pressure in the native pulmonary 
trunk remains high.[70] This finding may further stimulate 
to perform the ASO in transposition with intact septum 
during the first days of life, in order to improve the 
tissue characteristics of the neo-aortic valve. However, 
even after early ASO, distensibility of the aortic root is 
reduced, leading to increased left ventricular mass and 
diastolic dysfunction.[71,72] This finding was strongly 
associated with age, suggesting the usefulness of long-
term follow-up studies for early onset of degenerative 
cardiovascular disease.
In medium- and long-term follow-up studies after ASO, 
several risk factors for late neo-aortic root dilatation 
and aortic regurgitation have emerged. The presence of 
a VSD, previous pulmonary artery banding, older age at 
repair, and the association with CoA are patients factors 
associated with increased neo-aortic dilatation.[73-76] 
Technical factors such as acute angulation of the 
aortic arch after ASO[77] and closure of the VSD through 
the pulmonary artery,[74] have been associated with 
late aortic regurgitation and aortic dilatation in some 
reports. 
Freedom from moderate neo-aortic valve regurgitation 
was found to be between 70% and 81% at 15 years 
postoperatively.[73,74,78] The progression of regurgitation 
is slow and little progressive, is probably more related 
to the technique, and is correlated with the size of the 
neo-aortic annulus, not of the sinotubular junction.[75,78]
A dilated neo-aortic root (defined as larger than the 95th 
percentile) is seen in at least 50% of all patients after 
ASO.[74] Dilatation is more pronounced at the sinus level 
than at the sinotubular junction.[78] Hutter et al., noted 
rapid dilatation of the root during the first postoperative 
year, as seen after the Ross procedure, followed by 
growth towards normalization of the annulus and sinus 
over the next 10 years.[79] In contrast, Marino et al., 
described a gradual and continuous dilatation of the neo-
aortic root in ASO that does not seem to level off during 
the follow-up period. Aortic dilatation by itself is rarely 
associated with aortic valve regurgitation.[73] However, 
severe root dilatation appears to be closely related to 
significant neo-aortic valve regurgitation, mainly as a 
result of a time-dependent and reciprocal process.[76]
Freedom from aortic root reoperation was between 83% 
and 97% at 15 years, during reoperation preservation 
of the neo-aortic valve was rarely possible due to the 
asymmetry of the valve leaflets.[75,80]
Because the factor “time” is the principal determinant 
of late neo-aortic valve dysfunction and root dilatation, 
strict serial surveillance after ASO is mandatory.
Single ventricle situations
Since the introduction of staged procedures for patients 
with SV physiology two decades ago, an increasing 
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number of survivors with a Fontan circulation grow into 
adolescence and adulthood. 
When the native aortic valve functions as the only outlet 
valve, and no surgery to the original aortic root has been 
performed during staging, the chances of this valve 
deteriorating over time are small, as the architecture 
and wall characteristics are apt to sustain systemic 
pressures. However, when volume loading persists during 
a considerable period of time, and the Fontan completion 
is postponed at an older age, or when the aortic valve is 
bicuspid, the aortic root and ascending aorta may dilate 
over time and become aneurismal.[81]
After staged Fontan for hypoplastic left heart syndrome 
(HLHS) and its variants, the pulmonary valve functions 
as the systemic neo-aortic valve. In these situations, 
there is probably more reason for concern towards 
future valve function and neo-aortic dimensions. The 
physiological environment is comparable to the situation 
after a Ross procedure or an ASO, but with the additional 
risk of volume overload during the first and second 
Fontan stages, the presence of an asymmetrical patch 
in the ascending aorta and arch, and the possibility of 
recurrent distal arch stenosis during follow-up. Kojima 
et al., demonstrated increased pulse wave velocity 
in the ascending aorta in SV patients during routine 
catheterization at all Fontan stages.[82] Aortic stiffness 
was significantly higher in the group with dilated aorta, 
independent of aortic volume load. Histological analysis 
of a resected neo-aortic root, in a patient with a root 
aneurysm 10 years after Fontan, demonstrated no 
evidence of inflammation but rather fragmentation of 
elastic fibers, deposition of myxoid material, and loss of 
medial VSMC. These findings, commonly seen in other 
forms of aortopathy associated with bicuspid valves 
and connective tissue disorders, have been related to 
increased vascular stiffness in humans.[83]
Serial follow-up studies on the neo-aortic function 
after Fontan completion for SV are scarce. Neo-aortic 
regurgitation seems to be progressive over time: Mild 
systemic valve incompetence was noted in 25% during 
the first year after Norwood procedure,[84] and in 61% 
several years after total cavopulmonary anastomosis, 
but was rarely more than mild.[85]
In a study with a median follow-up of 9 years after 
Fontan completion, neo-aortic root progressively dilated 
out of proportion to body size over time, with 98% of 
patients having a root z-value of >2 at most recent 
follow-up. The authors concluded that early volume 
unloading had no beneficial impact on the size of the 
neo-aortic root.[85] Only a few case reports of quickly 
progressive neo-aortic root dilatation necessitating 
surgical intervention, have been published.[86-88] In 
the majority of cases, a valve-sparing operation was 
attempted, with variable results.
For now, neo-aortic root dilatation and neo-aortic 
regurgitation in the setting of HLHS have not a major 
impact on outcome, however, close observation is 
warranted, as cases of quickly progressive diameter 
increase have been described.[88]
DIAGNOSTIC MODALITIES
The cornerstone investigation in all pathologies described 
above, remains transthoracic echocardiography (TTE). It is 
the first line tool to delineate the exact valve anatomy, valve 
function, severity of regurgitation, and ventricular function. 
Measurement of the aortic root needs to be performed at 
four levels during end-diastole: Aortic annulus, sinus, 
sinotubular junction, and proximal ascending aorta. It 
may be difficult to appreciate the distal ascending aortic 
diameter on TTE. Sometimes better image quality can be 
obtained with transesophageal echocardiography, but 
usually some form of sedation is needed, and the mid-
segment of the aorta cannot be completely viewed.
To obtain a complete view of the aorta and its branches 
using a multi-plane modality, a magnetic resonance 
imaging study (MRI) is preferable to a CT scan, because 
of the absence of ionizing radiation, and because patients 
with dilated aortas will need multiple studies during 
their lifetime. MRI may be the preferred investigation 
when TTE is suboptimal, to exactly measure regurgitant 
valve fraction, and appreciate left ventricular function. 
Diameter measurements on CT and MRI are 1-2 mm 
larger than obtained on TTE, as the aortic wall segments 
are included.[89]
When following patients with aortic dilatation, not only 
the absolute diameter of the aortic segments is important, 
but also the diameter indexed to body surface area. 
This allows serial comparison of diameters in growing 
children, and may be also very useful in short statured 
adults. The upper limit of normal is defined as an indexed 
diameter of >21 mm/m2, significant dilatation of the 
aortic root as >25 mm/m2,[90] and significant risk for 
rupture from >27.5 mm/m2.[91]
The use of z-values to follow the aortic size is also validated. 
The z-value represents the number of standard deviations 
from the mean diameter, normalized for the patient’s body 
surface area, gender and age.[92] A mild aortic dilatation is 
defined as a z-value >1.9-3, moderate from 3-4.[93]
Some studies define significant aortic dilatation as 
observed versus predicted diameter >1.5.[50]
When performing serial follow-up, it is important to 
always compare the measurement obtained by the same 
diagnostic technique.
Guidelines for follow-up and treatment
Guidelines for the follow-up and surgical treatment of 
adult patients with valvular heart and thoracic aortic 
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disease are well established, and regularly updated.[94-96] In 
these guidelines, only BAV with thoracic aorta dilatation 
receives special attention. All guidelines are based on 
diameters; aortic size index is never used up to now.
Regarding follow-up, all patients with an aortic diameter 
of >40 mm should be follow-up regularly. When the 
diameter is >45 mm, and patients have a family history 
of dissection or show rapid progression, yearly imaging 
is mandated.
Surgery to the ascending aorta in BAV patients is 
mandated (Class IIa, level C):[95]
• for an ascending aorta of >50 mm, when the patient 
has a family history of dissection, or the size 
progression is >5 mm/year
• for an ascending aorta of >55 mm, when there are 
no risk factors
• for an ascending aorta of >45 mm, when surgery 
for the valve is obligatory; replacement of the aortic 
sinuses needs to be individualized
In contrast, nearly no guidelines exist for aortopathy in 
CHD.[97,98] In the ESC guidelines for grown-up CHD, only 
the following are mentioned:[97]
• surgical treatment for ascending aortic dilatation in 
CoA may be considered when the diameter is >55 mm 
(>27.5 mm/m2) or if rapid progression
• aortic surgery should be considered after ASO when 
the neo-aortic root is >55 mm providing adult stature 
(Class IIa/level C)
In the absence of guidelines for the other pathologies 
previously discussed, a pragmatic attitude is probably 
appropriate: As no case reports have appeared about 
ruptured aortas <55 mm in adult sized patients, this 
diameter should be used as a cut-off. A diameter of 
>60 mm is considered the hinge point for the ascending 
aorta, above which the chance for rupture increases 
exponentially.[99] In small children, rapid progression in 
size may urge faster intervention.
Medical therapy
Co-existent arterial hypertension in patients with CHD 
must be effectively treated, as hypertension has been 
shown to accelerate the aortic dilatation.[100]
The usefulness of medical treatment to prevent aortic 
expansion in normotensive patients with primary 
or secondary aortic dilatation related to CHD, is 
controversial. Despite a larger cohort of patients 
survives into adulthood, a paucity of data remains on 
the applicability of any medical therapy in the CHD 
patient group. The only existing guidelines are restricted 
to patients with Marfan disease with dilated aorta. As 
some histological and functional similarities have been 
shown between the aortas in CHD patients and those with 
Marfan syndrome, similar medical therapies have been 
recommended, however without strong clinical evidence. 
The most recent guidelines for the management of aortic 
aneurysm in non-Marfan patients recommend the use of 
β-blockers to decrease the blood pressure and the load 
on the aortic wall.[96] Another option may be to influence 
the angiotensin pathway, as the angiotensin-receptor 
blocker losartan was found to specifically inhibit the 
TGFβ-mediated activation pathway, inducing a decrease 
in MMP-2, MMP-9 and apoptosis in Marfan syndrome.[101]
It is clear that multicenter trials are needed to study 
medical therapy in patients with CHD-related aortopathy.
Surgical therapy
Valve-sparing procedures are usually preferred in 
growing children and young adults, whenever possible.[87] 
Surgery should be performed in centers with experience 
in thoracic aortic surgery.[102] Extensive discussion on this 
topic can be found in the literature.
CONCLUSION
Dilatation of the aortic root and the ascending aorta is 
frequently encountered in patients with CHD at initial 
presentation and during follow-up. As large cohorts of 
surgically treated patients survive into adulthood, more 
retrospective studies emerge discussing progressive 
aortopathy in patients with CHD. Specific guidelines 
about indication for medical and surgical treatment are 
largely lacking. Future recommendations should include 
indexed size measurements, adapted to growing children.
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